Literature DB >> 2161950

The repressing and enhancing functions of the herpes simplex virus regulatory protein ICP27 map to C-terminal regions and are required to modulate viral gene expression very early in infection.

L McMahan1, P A Schaffer.   

Abstract

The phenotypic properties of ICP27 temperature-sensitive and deletion mutants and the results of transient expression assays have demonstrated that ICP27 has a modulatory effect on viral gene expression induced by ICPs 0 and 4. In order to identify the regions of the ICP27 molecule that are responsible for its enhancing and repressing activities, 10 nonsense and 3 in-frame deletion mutations were introduced into the coding sequence of the cloned ICP27 gene. These mutant genes were tested in transient expression assays for their ability to complement an ICP27 null mutant and to enhance and repress expression from a spectrum of herpes simplex virus type 1 promoters in reporter CAT genes when expression was induced by ICP0 or ICP4. The results of assays with cloned mutant genes demonstrate that the ICP27 polypeptide contains two regions, located between amino acid residues 327 and 407 and residues 465 and 511, that contribute to its repressing activity. The amino acid region located between the two repressing regions (residues 407 to 465) is able to interfere with ICP27 repressing activity. None of the mutant genes exhibited efficient enhancing activity for any of the herpes simplex type 1 promoters tested, demonstrating that amino acids comprising the carboxy-terminal half of the ICP27 molecule, including the terminal phenylalanine residue, are required for wild-type enhancement as well as for efficient complementation of an ICP27 null mutant. Phenotypic characterization of an in-frame deletion mutant, vd3, and a previously isolated null mutant, 5dl 1.2 (A. M. McCarthy, L. and P. A. Schaffer, J. Virol. 63:18-27, 1989), demonstrated that ICP27 is required to induce the expression of all classes of viral genes very early in infection and confirmed the requirement for ICP27 later in infection (i) to repress early gene expression, (ii) to induce wild-type levels of delayed-early or gamma 1 gene expression, and (iii) to induce true late or gamma 2 gene expression. The vd3 mutant, which specifies an ICP27 peptide lacking the repressing region between residues 327 and 407, is able to (i) repress early gene expression, consistent with the repressing ability of the d3 mutation in transient expression assays, (ii) induce the synthesis of significant but reduced levels of delayed-early (gamma 1) proteins and no gamma 2 proteins (thus vd3 exhibits a late protein phenotype intermediate between that of the wild-type virus and 5dl 1.2), and (iii) confer altered electrophoretic mobility on ICP4, demonstrating a role for ICP27 in the posttranslational modification of this essential regulatory protein.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161950      PMCID: PMC249610          DOI: 10.1128/JVI.64.7.3471-3485.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Generation of an inverting herpes simplex virus 1 mutant lacking the L-S junction a sequences, an origin of DNA synthesis, and several genes including those specifying glycoprotein E and the alpha 47 gene.

Authors:  R Longnecker; B Roizman
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

2.  Activation of immediate-early, early, and late promoters by temperature-sensitive and wild-type forms of herpes simplex virus type 1 protein ICP4.

Authors:  N A DeLuca; P A Schaffer
Journal:  Mol Cell Biol       Date:  1985-08       Impact factor: 4.272

3.  Deletion mutants in the gene encoding the herpes simplex virus type 1 immediate-early protein ICP0 exhibit impaired growth in cell culture.

Authors:  W R Sacks; P A Schaffer
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

Review 4.  Multiple functional domains in the adenovirus E1A gene.

Authors:  E Moran; M B Mathews
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

5.  An adenovirus E1a protein region required for transformation and transcriptional repression.

Authors:  J W Lillie; M Green; M R Green
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

6.  Regulation of the herpes simplex virus type 1 late (gamma 2) glycoprotein C gene: sequences between base pairs -34 to +29 control transient expression and responsiveness to transactivation by the products of the immediate early (alpha) 4 and 0 genes.

Authors:  M Shapira; F L Homa; J C Glorioso; M Levine
Journal:  Nucleic Acids Res       Date:  1987-04-10       Impact factor: 16.971

7.  Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110.

Authors:  N D Stow; E C Stow
Journal:  J Gen Virol       Date:  1986-12       Impact factor: 3.891

8.  The products of herpes simplex virus type 1 (HSV-1) immediate early genes 1, 2 and 3 can activate HSV-1 gene expression in trans.

Authors:  R D Everett
Journal:  J Gen Virol       Date:  1986-11       Impact factor: 3.891

9.  Identification of immediate early genes from herpes simplex virus that transactivate the virus thymidine kinase gene.

Authors:  I H Gelman; S Silverstein
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  Herpes simplex virus type 1 ICP27 is an essential regulatory protein.

Authors:  W R Sacks; C C Greene; D P Aschman; P A Schaffer
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

View more
  90 in total

1.  Herpes simplex virus ICP27 induces cytoplasmic accumulation of unspliced polyadenylated alpha-globin pre-mRNA in infected HeLa cells.

Authors:  P Cheung; K S Ellison; R Verity; J R Smiley
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Herpesvirus mRNAs are sorted for export via Crm1-dependent and -independent pathways.

Authors:  T M Soliman; S J Silverstein
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Processing of alpha-globin and ICP0 mRNA in cells infected with herpes simplex virus type 1 ICP27 mutants.

Authors:  K S Ellison; S A Rice; R Verity; J R Smiley
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 4.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

5.  Herpes simplex virus IE63 acts at the posttranscriptional level to stimulate viral mRNA 3' processing.

Authors:  J McLauchlan; A Phelan; C Loney; R M Sandri-Goldin; J B Clements
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  Stress-induced cellular transcription factors expressed in trigeminal ganglionic neurons stimulate the herpes simplex virus 1 ICP0 promoter.

Authors:  Devis Sinani; Ethan Cordes; Aspen Workman; Prasanth Thunuguntia; Clinton Jones
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

7.  Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis.

Authors:  L I Strelow; D A Leib
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Herpes simplex virus trans-regulatory protein ICP27 stabilizes and binds to 3' ends of labile mRNA.

Authors:  C R Brown; M S Nakamura; J D Mosca; G S Hayward; S E Straus; L P Perera
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  The herpes simplex virus regulatory protein ICP27 contributes to the decrease in cellular mRNA levels during infection.

Authors:  M A Hardwicke; R M Sandri-Goldin
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  UL69 of human cytomegalovirus, an open reading frame with homology to ICP27 of herpes simplex virus, encodes a transactivator of gene expression.

Authors:  M Winkler; S A Rice; T Stamminger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.